Regeneron Pharmaceuticals, Inc.

REGNNASDAQHealthcare● Active

$623.52

$-11.93(-1.88%)

Market Cap$64.2B

P/E Ratio—

52W High$821.11

52W Low$476.49

Avg Volume831K

Open$638.04

Beta0.24

Net Income Financials Revenue

Regeneron Pharmaceuticals, Inc. (REGN) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

REGN · net income · updated Jun 8, 2026

Core profitability metrics

REGN · net income · margin · TTM · CAGR

Net income was $4.50B for FY2025 (fiscal year ending 2025-12-31), up 2.1% year-over-year. Net profit margin was 31.4%. Based on available data, Regeneron Pharmaceuticals, Inc. has been profitable since at least 2012.

FY2025 Net Income$4.50B▲ +2.1% YoY

Trailing 12M (TTM)$4.42Btrailing 4 quarters sum

Net Profit Margin31.4%$4.50B ÷ $14.34B

YoY Change+2.1%—

5-Year CAGR+5.1%FY2020 → FY2025

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2012

▸ FMP /income-statement · Annual · REGN net income history · REGN profit margin

Annual net income data

REGN · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$4.50B▲ +2.1%31.4%$14.34B

FY2024$4.41B▲ +11.6%31.1%$14.20B

FY2023$3.95B▼ 8.9%30.1%$13.12B

FY2022$4.34B▼ 46.3%35.6%$12.17B

FY2021$8.08B▲ +129.9%50.3%$16.07B

Net income vs peers (Healthcare)

REGN vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Regeneron Pharmaceuticals, Inc.YOU

REGN

$4.50B+2.1%31.4%

17%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Regeneron Pharmaceuticals, Inc. (REGN) reported net income of $4.50B for FY2025 (fiscal year ending 2025-12-31), up 2.1% year-over-year. The net profit margin was 31.4% — meaning the company kept $0.31 of every dollar of revenue as profit.

Based on available data, Regeneron Pharmaceuticals, Inc. has been profitable since at least 2012. Net income reached a peak of $8.08B in FY2021. Data available for 15 fiscal years.

Regeneron Pharmaceuticals, Inc.'s net profit margin was 31.4% for FY2025, based on the latest annual results.

Investors sometimes search for "Regeneron Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from REGN net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

REGN net income · 5 questions

Regeneron Pharmaceuticals, Inc. is profitable. The company reported net income of $4.50B for FY2025, a net profit margin of 31.4%. Net income was up 2.1% year-over-year. Based on available data, Regeneron Pharmaceuticals, Inc. has been profitable since at least 2012.

is REGN profitabledoes REGN make a profitREGN profitabilityREGN profitable company

▸ Source: FMP /income-statement · GAAP · Regeneron Pharmaceuticals, Inc. · Regeneron Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026